Kristen Hege, Bristol Myers Squibb SVP, early clinical development, oncology/hematology and cell therapy (Illustration: Assistant Editor Kathy Wong for Endpoints News)

Q&A: Bris­tol My­er­s' Kris­ten Hege on cell ther­a­py, can­cer pa­tients and men­tor­ing the next gen­er­a­tion

Kris­ten Hege leads Bris­tol My­ers Squibb’s ear­ly on­col­o­gy dis­cov­ery pro­gram car­ry­ing on from the same work at Cel­gene, which was ac­quired by BMS in 2019 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.